Physician profile
Stephen Wade
NPI 1114067261
$15,772.78
in general payments reported to CMS, 2019-2025
26 companies · $2,646 in 2025
The $2,646 reported for 2025 was more than what 89% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,807 · 2020: $775 · 2021: $777 · 2022: $490 · 2023: $1,665 · 2024: $2,613 · 2025: $2,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488 · Travel and Lodging: $3,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.48 |
| Travel and Lodging | $3,435.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,355.39 | 2019-2023 | Senza |
| Boston Scientific Corporation | $2,836.71 | 2019-2024 | Wavewriter Alpha Prime 16, Intracept |
| Saluda Medical Americas, INC. | $2,472.99 | 2023-2025 | Evoke, Evoke Scs |
| Abbott Laboratories | $1,921.30 | 2019-2022 | |
| Bioventus LLC | $1,379.91 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $698.03 | 2023 | Iovera, Zilretta |
| Depuy Synthes Sales INC. | $631.36 | 2023-2025 | Orthovisc, Monovisc |
| Globus Medical, INC. | $417.51 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $365.37 | 2019-2020 | |
| Si-Bone, INC. | $357.62 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.33 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $188.69 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $168.61 | 2022-2024 | Visco-3 Sodium Hyaluronate |
| Curonix LLC | $137.25 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Zimvie INC. | $117.45 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $107.25 | 2024 | O-Arm |
| Relievant Medsystems, INC. | $84.64 | 2019 | |
| Biodelivery Sciences International, INC. | $66.55 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $56.77 | 2022-2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $50.08 | 2025 | |
| Scilex Pharmaceuticals INC. | $43.33 | 2019-2020 | |
| Mdd US Operations, LLC | $29.45 | 2019-2020 | |
| Daiichi Sankyo INC. | $26.37 | 2019 | |
| Horizon Therapeutics Plc | $26.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.20 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.